about-me variable
MIMETAS invites you to their event

Screening of renal drug-transporter interactions in a 3D Human Proximal-Tubule-on-a-Chip

About this event

Better models for studying nephrotoxicity are desperately needed.

Current in vivo or in vitro models do not always suffice. 

They can lack in throughput, physiological relevance, and predictive power.

In the first webinar of this series, you learned how to develop an in vitro 3D model of fully polarized renal proximal tubular epithelial cells expressing active transporters that are necessary for your studies in MIMETAS OrganoPlate®.

In this webinar, you will learn how this model was further validated through drug-drug interaction studies focusing on two important efflux mechanisms in renal proximal tubules. Namely, the P-glycoprotein and the combined activities of Multidrug Resistance Proteins 2 and 4.

Imagine your nephrotoxicity studies bringing reliable, consistent, and physiologically relevant results quickly and by using human cell lines.

The OrganoPlate® platform is already successfully being used by the top 10 pharma as well as by hundreds of academic researchers worldwide.

What you will learn

➡️ How to choose a cell line and culture platform for reliable 3D in vitro nephrotoxicity studies

➡️ How to evaluate if your 3D in vitro model is physiologically relevant

➡️ How to study drug transport in 3D

➡️ How to easily qualify your in vitro 3D renal proximal tubule model with clinically relevant compounds

What others have said about the OrganoPlate®

“With the MIMETAS OrganoPlate, we developed a 3D brain-on-a-chip model that made it easy to do high-throughput and high-content imaging to evaluate the acute toxicity of neurotoxins. The OrganoPlate allowed the study of membrane-free vascular formation in a dynamic environment and further provided reliable and repeatable experiments with strong imaging capability.” — Dr. Yeoheung Yun, Associate Professor at North Carolina A&T State University 

 “Often you have to compromise: it’s either the throughput or it’s the complexity of the model. Getting both in the same platform…no other platform can do that!” – Senior Scientist from top pharma

 Enter your data in the text field above and click on the signup button to get immediate access to the webinar.

This is a replay of a recorded webinar. Nevertheless, feel free to type your questions in the chat-box. We will answer you by email within 24 hours.

Related publications


MIMETAS offers OrganoPlates and develops human tissue and disease models for tomorrow’s medicines, chemicals and food.